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Abstract
Background: To establish a distant metastasis (DM) cells must disseminate from the primary tumor and overcome
a series of obstacles, the metastatic cascade. In this study we develop a mathematical model for this cascade to
estimate the tumor size and the circulating tumor cell (CTC) load before the first metastasis has formed from a
primary breast cancer tumor.
Methods: The metastatic cascade is described in discrete steps: 1. local tumor growth; 2. dissemination into
circulation; 3. survival in circulation; 4. extravasation into tissue; and 5. growth into a metastasis. The model was
built using data and relationships described in the literature to predict the relationship between tumor size and
probability of distant metastasis for 38715 patients with surgically removed TXNXM0 primary breast cancer from the
Netherlands Cancer Registry. The model was calibrated using primary tumor size, probability of distant metastasis
and time to distant metastasis for 1489 patients with stage T1BNXM0 (25% of total patients with T1BNXM0). Validation
of the model was done with data for all patients.
Results: From the time to distant metastasis of these 38715 breast cancer patients, we determined a tumor
doubling time of 1.7 ± 0.9 months. Fitting the data for 25% of T1B patients estimates a metastatic efficiency of 1
metastasis formed per 60 million disseminated tumor cells. Validation of the model to data of patients in all T-stages
shows good agreement between model and epidemiological data. To reduce the 5-year risk of distant metastasis
for TXNXM0 from 9.2% to 1.0%, the primary tumor needs to be detected and removed before it reaches a diameter
of 2.7 ± 1.6 mm. At this size, the model predicts that there will be 9 ± 6 CTC/L blood.
Conclusions: To reduce the rate of distant metastasis in surgically treated TXNXM0 breast cancer to 1%, imaging
technology will need to be able to detect lesions of 2.7 mm in diameter or smaller. Before CTC detection can be
applied in the early disease setting, sensitivity will need to be improved by at least 15-fold and combined with
technology that minimizes false positives.
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Background
The majority of deaths from cancer are due to distant
disseminated disease rather than the primary tumor [1].
While metastases are often discovered years after surgical
removal of the primary tumor, probably at least one me-
tastasis was already present at the time of surgery. Under-
standing of the formation of distant metastasis (DM) is
crucial for the reduction of the recurrence rate. For the
successful colonization of a secondary site a cancer cell
must complete a series of steps to become a clinically de-
tectable lesion, baptized the metastatic cascade [2-5]. This
cascade is an inefficient process, generating metastasis by
sending large numbers of malignant cells into the circu-
lation [6,7]. The number of cells disseminated and the
efficiency of metastasis formation contribute to the prob-
ability that a metastasis has formed. Assays for enumer-
ation of circulating tumor cells (CTC) in blood can provide
the number of disseminated cells. The CTC are the new
seeds of a tumor, and as such provide an opportunity to
estimate the metastatic efficiency. Due to metastatic ineffi-
ciency, the presence of CTC does not imply that metasta-
ses already exist. Identification and enumeration of CTC
at or before the diagnosis of the primary tumor may allow
estimation of the probability of DM being present and
thus help identify patients who will benefit from more
intensive adjuvant therapy after surgical removal of
the primary lesion. Here we developed a model for the
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metastatic cascade and estimated the sensitivity needed
for imaging and CTC enumeration to detect a primary
tumor before it has formed DM.
Methods
Distant metastasis statistics
The probability of DM and time to DM was determined
based on patients selected from the population based
Netherlands Cancer Registry (NCR, www.iknl.nl). Specially
trained registrars access the patient files to gather data re-
garding patient, tumor characteristics, and treatment for
all malignancies in all hospitals in the Netherlands. Tumor
size is determined by specialized pathologists. From the
registry, we selected women who were diagnosed between
2003 and 2006 with pathological stage T1ANXM0-T2NXM0
primary invasive breast cancer, being 25 years or older
at time of diagnosis and had mastectomy or breast con-
serving surgery. Patients were excluded if any evidence
of residual tumor was found after surgery. Patients were
followed until at least five years after diagnosis and both
occurrence and date of DM were registered. Time be-
tween diagnosis and occurrence of DM is indicated with
the mean and standard deviation. Probability of a DM
within the five years of follow-up and the 95% confidence
interval of DM were determined by Poisson statistics. The
study protocol was approved by the NCR Privacy Council
and assured that all necessary consent from the patients
were obtained.
Parameter fitting
A numerical model for the development and detection of
DM was developed and tested in Matlab 2009a (Mathworks,
Natick, MA). The two essential elements in the model are
the number of cells disseminated into circulation with a cer-
tain time interval and the probability of metastatic success
of each cell. The number of metastases formed is described
by a binomial distribution, which is approximated by apply-
ing the Poisson limit theorem. The resulting cumulative
distribution function was compared to a pseudo random
number generated by Matlab. The time to DM in the
model was defined as the time between removal of the
primary tumor and the time when the first DM reaches
8 mm in diameter (T1B). The mean and standard devi-
ation of the doubling time was determined from the
time to DM. CTC concentration was fit to available lit-
erature values; patients with metastatic disease have
3.0 CTC/mL (5–95 percentile: 0.02-417 CTC/mL) [8-11],
and patients with early stage breast cancer have CTC at a
mean concentration of 0.03 CTC/mL (range of estimates
0.01-0.05 CTC/mL) [12-15].
The product of dissemination rate and metastatic effi-
ciency was fit to the probability of DM for 25% of patients
with stage T1B, running 10,000 iterations and randomizing
doubling time for each iteration. Stage T1B was selected
for fitting because it is the smallest frequently discovered
tumor, typically discovered when it reaches a diameter
of 8 mm. After fitting the data on a subset of T1B pa-
tients we validated the model by comparing predicted
and actual probability of DM for all patients grouped by
T-stage (T1A-T2).
Results
Model for formation of distant metastasis
The steps in the metastatic cascade are summarized in
Figure 1. 1). A tumor grows locally. 2). Cells disseminate
from the primary tumor. 3). The tumor cells that ultim-
ately survive in the circulation. 4). Arrest of tumor cells
in the microcirculation of an organ and potential ex-
travasation into the surrounding tissue. The extravasated
tumor cells can either 5A). Survive as a singular dor-
mant cell, 5B). Form a micro metastasis, or 5C). Grow
into a macro metastasis. While it is unknown what trig-
gers a primary tumor to start shedding cells into the
blood stream, this shedding starts well before the primary
tumor is detectable by current imaging techniques [16-18].
We developed a mathematical model for the formation of
metastasis using relationships described in literature for
each of these steps. Steps 3,4 and 5C together are the
probability that a disseminated cell forms a macro metas-
tasis, i.e. the metastatic efficiency (metastatic).
In the model the following conventions are applied: the
number of cells is described with N, the dissemination
Figure 1 Steps in the metastatic cascade. Parameters related to
each step are shown near the description of each step. Cells in
tissue are indicated in light gray, cells in blood or in transition
between blood vessel and tissue are indicated in black. Local
growth (step/equation 1) is needed to provide sufficient
disseminated cells. Steps 2–5 are typically referred to as the
metastatic cascade (equations S3-S5, S8). Step 5 has multiple
outcomes, with cells surviving, but not replicating (5A), briefly or
slowly replicating (5B) or rapidly replicating (5C).
Coumans et al. BMC Cancer 2013, 13:283 Page 2 of 12
http://www.biomedcentral.com/1471-2407/13/283
rate with R, the diameter with D, the doubling time
with DT and other constants with C. Subscripts are
used to differentiate different N. The formation of distant
metastasis is described with functions for the steps, depicted
in Figure 1, see Additional file 1: Supplemental S1 for a
more elaborate derivation:
1. Local growth: In a comparison of functions typically
used to describe tumor growth (exponential,
Gompertz or logistic), the logistic function fit best
[19], equation 1:
Nmass t   Nmax
1 N1=4max1
 
eln 2  t=4 DT
 4

Nmax
1 Nmaxeln 2  t=DT 1=4
h i4
1
Gompertz and logistic functions have a slowing
growth rate as the tumor reaches a maximum size
Nmax (N = number of tumor cells) at a certain time
(t). Nmax is typically chosen at 10
12 cells/1 kilogram
[19]. We assume metastases grow according to
equation 1. Changes in growth rate due to
occurrence of growth enhancing mutations or due
to chemo or hormonal therapy are not explicitly
considered in any of the growth models.
2. Dissemination to circulation: The relationship
between tumor diameter (Dmass) and the number of
disseminated cells (Ndiss) is assumed linear and is
derived from murine data comparing CTC counts to
the diameter of the primary tumor [20-23]. To derive
the diameter of the lesion from the number of cells
(Nmass) we assumed a spherical lesion, cells into which
disseminates the bloodstream at a rate (Rdiss):
Rdiss  Cdiss:Dmass 2
3,4,5C. Formation of a metastasis: The relationship
between the number of cells injected into the
circulation and the number of macroscopic
metastases is linear [24-26], with a slope metastatic
the metastatic efficiency. We now find the total
number of metastases:
Ntotal macro met  metastatic:Rdissdt 3
In this equation, the number of metastases formed is
equal to the metastatic efficiency times the total
number of cells disseminated from the tumor. The
rate of cell dissemination (Rdiss) is measurable by
detecting the number of CTC, while the metastatic
efficiency (metastatic) may be measurable either by
genotyping these CTC or the primary tissue.
Below we listed the assumptions of the model with
their impact:
1. Growth of the primary tumor is described by a
logistic function. Studies that determine the growth
functions do so on relatively large tumors, Table 1.
The shape of the growth function when the tumor
consists of only a few cells in size is not known.
2. A single malignant breast cell with a size of 10-6 mm3,
starts to grow and disseminate tumor cells into the
blood. Although it is unlikely that a tumor starts
dissemination from a size of one cell, the starting
size only marginally affects the metastatic efficiency.
For example the estimate for metastatic efficiency is
increased by 1%, if dissemination does not start
immediately, but starts once the tumor reaches a
size of 0.1 mm (1000 cells).
3. Each of the disseminated cells has the same
probability of forming a distant metastasis (DM). It
is likely that only a limited number of cells are
capable of metastasizing, for example because part
of disseminated cells are not viable, or do not have
the features needed for metastasis. The estimated
metastatic efficiency is the average efficiency. If only
1% of cells are capable of metastasizing, the
metastatic efficiency of those cells would be 100 times
larger than our estimate over the total number of
cells. This assumption does not affect the fit
parameters, but could result in enhanced metastatic
efficiency of cells disseminated from metastases.
4. The probability of forming a DM is constant over
time, i.e. tumor evolution is not considered. While
we expect that metastatic efficiency increases over
time, the literature does not describe quantitative
data for such evolution. If tumor evolution is rapid,
Table 1 Human breast cancer values for doubling time
Tumor Doubling time (months)
Publication N size (mm) Median Range
Lundgren 1977 [27] 13 N/A 6.9 1.4 – 13.0 a
Heuser 1979 [28] 32 14 10.6 b 3.6 – 31.0 a
Von Fournier 1980 [29] 100 17 6.6 b 2.1 – 20.6 c
Galante 1981 [30] 196 N/A 2.0 N/A
Tabbane 1989 [31] 75 N/A 3.8 0.5 – 25.3 a
Kuroishi 1990 [32] 142 N/A 5.7 b 0.4 – 42.4 a
Spratt 1993 [19] 448 9 8.5 5.0 – 15.7 d
Peer 1993 [33] 236 >10 5.0 1.5 – 17.1 e
Tilanus-Linthorst 2005 [34] 47 12 2.0 b 0.4 – 18.6 a
Weedon-Felkjaer 2008 [35] 969 15 3.1 1.0 – 9.6 d
Millet 2011 [36] 37 9 11.2 b 222.9 – 146.6 a
N/A: not available, a minimum-maximum, b mean, c 2.5-97.5 percentile, d 25-75
percentile, e 68% confidence interval.
Coumans et al. BMC Cancer 2013, 13:283 Page 3 of 12
http://www.biomedcentral.com/1471-2407/13/283
our estimated metastatic efficiency is effectively fit
to the time-period just before tumor discovery.
5. The probability of forming a DM and the
dissemination rate are not dependent on the growth
rate of the primary tumor. Considering the high
incidence of recurrence within the first 5 years
compared to years 6–15, metastatic efficiency or
dissemination rate probably are smaller for slower
growing tumors. If, for example, 75% of
recurrences are found in the first five years
(doubling time < 3 months), 20% of recurrences
in years 5–15 (doubling time 3–9 months), and
5% of recurrences in years 15–25 (doubling time
9–15 months), the metastatic efficiency/dissemination
rate for a 0–3 month doubling time would be
approximately 6-fold higher than a 4–9 month
doubling time and approximately 24-fold higher than
a 10–15 month doubling time.
6. Both the rate of dissemination and the probability of
distant metastasis formation are independent of the
cancer type. We need to make this assumption
because (1) data on CTC concentrations versus
cancer type is not available, and (2) data on cancer
types for the patients in our data set is not available.
In another study, the five year risk of recurrence for
patients with triple negative breast cancer was
estimated to be 2.6 fold higher than for patients with
other breast cancers [37]. This implies that the
product of dissemination rate and metastatic
efficiency needs to be approximately 2.6 fold higher
for patients with triple negative breast cancer.
7. Disseminated cells are not temporarily ‘stored’ in the
bone marrow (tumor dormancy). In the model we
assume the transit from primary tumor to metastatic
site occurs within days. Temporary storage
(dormancy) of cells in the bone marrow at the
metastatic site, would result in a delay in the start of
growth, and thus in an underestimation of the
doubling time. For long delays the recurrence would
likely be pushed outside the 5-year window, and for
small delays the doubling time is marginally affected.
For example, if a typical delay would be four
months, the previous doubling time estimate of
1.7 months would become 1.5 months.
8. All primary tumors are removed once they reach a
predefined (constant) diameter corresponding to the
median size at each stage. This assumption has a
negligible impact on growth rate due to the small
range of sizes within each T-stage.
9. In case of DM at least one metastasis was formed
prior to surgery. This assumption means that all
metastases originate from the primary tumor, and
implies no patients formed a second primary tumor.
This assumption leads to an overestimation of the
rate of recurrence, and thus an overestimation of the
metastatic efficiency. For example, if 10% of DM
were misclassified and actually a second primary, the
risk of recurrence is reduced by 10% and the
metastatic efficiency is reduced by 10%.
10.The probability of DM is defined as the probability
that at least one metastasis was present at the time
of surgery, continues to grow and is discovered once
it has reached a size of 8 mm. Changing the size at
which a tumor is discovered affects the estimated
growth rate. For example, if the typical tumor is
discovered at a size of 15 mm, the estimated
doubling time is 1.5 months instead of 1.7 months.
11.For fitting of the model, the primary tumor is
detected when it reaches a size of 8 mm (stage T1B).
This assumption has negligible impact on growth
rate due to the small range of sizes within each T-stage.
12.For validating the model, the primary is detected
when it reaches the median size representative of
each TX stage. This assumption has negligible
impact on growth rate due to the small range of
sizes within each T-stage.
13.Cardiac output is 5 L/minute. The cardiac output is
used to convert the CTC concentration to the
dissemination rate. A different cardiac output only
affects the dissemination rate and metastatic
efficiency. A cardiac output of for example 6 L/minute
would reduce the estimated dissemination rate by
17%, but increase the estimated metastatic efficiency
by 20%.
14.Dissemination rate is proportional to tumor
diameter. Literature values in murine models
[20,23,38-42] suggest a linear relationship between
dissemination rate and tumor diameter. However,
most of these determine three data points. The
model does not fit the epidemiological data if we
assume the dissemination rate to be proportional to
the tumor surface area, or the number of cells in
the tumor.
Distant metastasis statistics
Of 42318 patients matching our search criteria, 38715
(91%) patients were included, see Figure 2 for exclusion
details. The probability of DM after surgery and the time
to DM from stage T1A – T2 invasive breast carcinoma
patients, without known metastases at time of diagnosis
(NXM0) was determined and shown in Figure 3. Three
thousand five hundred and fifty patients (9.2%) devel-
oped DM within five years after surgery. The overall
time to DM was 32.0 ± 17.2 months. Variation in mean
time to DM between different T-stages is small (range
30.2 – 35.1 months). 95% of detected primary tumors
are 5 mm or larger (median 17 mm). Information of both
T-stage and diameter of the primary was available for
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33876 (88%) patients in our database. We assumed that
the 12% of patients with known T-stage, but without data
for the diameter of the primary tumor had the same diam-
eter as the 88% of patients with this data. Probability of
DM, time to DM and median size by stage was used to fit
the model (equation 3) to the clinical data for 25% of
patients with T1B primary tumors. Of 1493 T1B patients
used to fit the model, 42 developed DM (2.8%), while in
the full data set, 195 of 5975 (3.3%) T1B patients devel-
oped DM. We compare the data from the model fit with
values reported in the literature for both human and
murine studies in Table 2, with more detailed informa-
tion in Additional file 1: Table S1.
Tumor doubling time
From the time to DM of the 38715 breast cancer patients,
we determined a doubling time (DT) of 1.7 ± 0.9 months.
Human values for DT are estimated by fitting a growth
model to imaging data reported in the literature, see
Additional file 1: Table S2. The median DT is estimated at
5.7 months (range 2.0 to 11.2 months) in these reports.
Formation of metastases and dissemination rate
The probability of forming a metastasis is primarily deter-
mined by (1) the number of cells entering the circulation
and (2) the probability that each of these cells forms a me-
tastasis (metastatic). The number of cells entering the cir-
culation is a function of the dissemination rate (Rdiss) and
the elapsed time, which is affected by the tumor doubling
time (DT). For a given DT, the probability to form a
metastasis before surgery is determined by the product
Figure 2 Exclusion diagram. Of 42318 patients included by the
initial search criteria, 3603 (9%) were excluded for the reasons detailed
in the diagram. The distribution of patients by T-stage, node (N) status
and therapy after surgery are shown for the 38715 included patients.
Figure 3 Probability of distant metastasis by T-stage for patients who are NXM0. Total n = 38715, number of DM n = 3550. Whiskers
indicate 95% confidence intervals determined using Poisson statistics. Below the T-stage further statistics are shown, including median diameter
in mm, number of patients included, number of patients with a DM as well as mean and standard deviation of time to DM. The model was fit to
25% of the data for T1B tumors. In this subset of the data, there were 42 occurrences of DM in 1489 patients (2.8%) compared to 195 occurrences
in 5957 patients (3.3%). Probability of DM for T1A, T1C and T2 was predicted using the model fit to T1B data.
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of metastatic and Rdiss. We derived metastatic from this
product by assuming that Rdiss is directly related to the
CTC concentration, as described in Additional file 1:
Supplemental S2. The CTC concentration reported for
primary breast cancer before surgery is 0.03 CTC/mL
(range 0.01-0.05 CTC/mL [12-15]). We now find a dis-
semination rate for an 8 mm tumor of 280 CTC/h · g
tumor (range 90–470 CTC/h · g tumor) and a metastatic
efficiency of 1.7 · 10-8 metastases formed per disseminated
cell (range 1.3 · 10-8-4.2 · 10-8), or approximately 60 million
disseminated cells per formed macrometastasis.
For comparison, the dissemination rate can be estimated
from two human studies which determined the CTC con-
centration in the efferent vein of colorectal and renal can-
cer, Table 3, with a median estimate of 3,100 CTC/h · g
tumor, and an estimated range of 90–78,000 CTC/h · g.
Metastatic efficiency has not yet been estimated in humans.
In murine models, the dissemination rate determined by
various techniques spans a wide range of nearly 7 orders
of magnitude, Table 2 and Additional file 1: Table S1.
The median estimate is 1.0 · 105 CTC/h · g (range 0.15 to
8.7 · 106 CTC/h · g). Metastatic efficiency has been deter-
mined either from the number of macro metastases formed
from injection of a known number of malignant cells, or
by observing the individual probabilities in the meta-
static cascade by means of intra-vital video microscopy
(IVM, [43]). Methods, which determined the meta-
static efficiency from injection of a known number of
cells, estimated metastatic at 0.005% (range 0.0001-6%),
Additional file 1: Table S3. From the IVM studies we
find a comparable metastatic of 0.011%, primarily caused
by the low probability of extravasated cells to form a
macro metastasis, Additional file 1: Supplemental S3.
CTC in a metastatic patient are present at a concen-
tration of 3 CTC/mL of blood [11], however a 100-fold
lower concentration is detected in patients before sur-
gery. In our model the number of circulating tumor cells
is linked to the total tumor size. While the total tumor
size of all lesions is larger for a metastatic patient, the
difference is not sufficient to cause such a high change
in CTC concentration. To achieve the higher CTC con-
centration post-surgery, we increased the dissemination
rate by 25-fold for all metastatic lesions. We could also
achieve this CTC concentration by increasing the meta-
static efficiency 10,000-fold. Either scenario, or a com-
bination, is conceivable, since a cell that has completed
the metastatic cascade has proven to be capable of
dissemination into the circulation and of formation of
a metastasis.
Sensitivity needed for radiographic imaging and CTC
detection to detect a tumor before it gives rise to metastasis
The model was used to predict the technology needs for
detection of tumors before metastasis can occur. The
values used for the model are provided in Table 2. In
Figure 4 an example is shown of a T1B breast tumor.
Panel A shows the development of the total tumor mass
and the tumor cell number per equation 1. The black
line represents the case for which the tumor is surgically
removed and the gray line the case for which the tumor
is not removed. In panel B, the solid black line shows
the maximum diameter of the tumor. This diameter is
important for detection of a tumor by an imaging
method. In this case, the T1B tumor is detected when it
reaches 8 mm, 3.4 years after its inception, and is surgi-
cally removed. If an imaging system is employed to
detect all lesions in a patient, it must be capable of
identifying the smallest lesions. The dashed line in panel B
shows the diameter of the smallest lesion at times multiple
lesions exist. In Figure 4, the tumor has seeded a metasta-
sis 2.8 years after initiation of the tumor. At the time of
surgery this lesion has a diameter of 70 m; undetectable
by imaging. The total number of metastases is shown in a
solid gray line on the secondary y-axis. The number of
metastases is relatively stable from 3.4 years to ~5.5 years
after surgery, but rapidly increases after 6 years because
Table 2 Metastatic cascade parameter estimates from our model, human and murine studies
Parameter Model Human Murine
Doubling time (months) 1.7 ± 0.9 5.7 (2.0-11.2)
Dissemination rate (CTC/h/g) 280 (90–470) 3.1 · 103 (90–78 · 103) 1.0 · 105 (1.5 · 10-1-8.7 · 106)
Metastatic efficiency 1.7 · 10-8 (1.3 · 10-8-4.2 · 10-8) 7 · 10-5 (1 · 10-6-6 · 10-3)
Literature values are the median of all estimates with the range of estimates in parenthesis. Detailed data for each publication is accessed through Additional file 1:
Table S1.
Table 3 Human values for dissemination rate
Publication Cancer N Diameter (mm) Disseminated cells a Rdiss (CTC/h · g)
b
Glaves 1988 [44] Renal 15 5-10 890 78 · 103
Wind 2009 [45]c Colon 13 4.1 ± 1.4 0.05 90
Wind 2009 [45]d Colon 18 5.0 ± 2.3 3.2 3.1 · 103
a mean CTC/mL tumor efferent blood, b for spherical tumor, c laparoscopic surgery, d open surgery.
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the metastasis has become sufficiently large to make for-
mation of new metastases sufficiently probable. Panel C
shows the CTC concentration in solid black and the prob-
ability of forming the first DM is solid gray on the second-
ary y-axis. To reduce the probability of DM from 9.2% in
the patients included in our study to 1%, the tumor needs
to be detected by the time it reaches 2.7 ± 1.6 mm, or
when the CTC concentration is 9 ± 6 CTC/L whole blood.
Discussion
The most effective therapy to treat breast cancer is to sur-
gically remove the primary tumor before it has formed a
distant metastasis (DM). Unfortunately the technology
available to detect the presence of DM at the time of
diagnosis cannot accurately make this determination
and a large portion of patients receiving adjuvant therapy
do not benefit from this therapy whereas others could
have benefitted from adjuvant therapy they did not re-
ceive. To identify those patients at risk for DM the trad-
itional TNM-classification has been complemented with
differentiation grade, peri-tumor vascular invasion, es-
trogen, progesterone, Her2neu receptor expression and
more recently through molecular characterization of
the tumor [46-51]. Although improvement in the risk
assessment helps to identify the patients that need add-
itional therapy after surgical removal of the primary tumor,
detection of the actual presence of tumor cells beyond
the primary tumor is preferred. Indeed the presence of
micrometastases in bone marrow [52,53] and tumor
cells in blood [12-14,54] of breast cancer patients have
been associated with an increased risk for disease recur-
rence, but have not become part of clinical practice
partly because the current technology lacks sufficient
sensitivity and specificity. The observations that CTC
have been detected in patients years after a diagnosis
and treatment of breast cancer with curative intent fur-
ther challenges the technology to identify those CTC
characteristics that predict imminent relapse [55,56].
To identify the basic requirements for detection of DM
we have modeled the probability that a DM has been
formed prior to surgery. Three key components of
this probability are the tumor doubling time (DT), the
rate of tumor cell dissemination (Rdiss), and the prob-
ability of successful completion of the metastatic cascade
Figure 4 Application of the model to estimate the technology requirements for radiographic imaging and CTC detection to reduce the
probability of distant metastasis to below 1%. Panel A shows the time needed to develop a tumor mass and the number of tumor cells for a
stage T1B tumor removed by surgery (black line) or not removed by surgery (gray line). Panel B shows the maximum (black solid line) and
minimum size (black dashed line) of the primary tumor and/or metastasis and the number of metastasis in gray. Minimum size is only shown
when 2 or more lesions exist, the formation of the second lesion before and after surgery are indicated with a vertical black arrow. Panel C shows
the development of the CTC concentration in black, and the cumulative probability that a first metastasis has occurred in gray. The black vertical
dashed line indicates the time at which the primary tumor is surgically removed in our model. The cumulative probability is used to determine
the detection goal (vertical dashed gray line); the time when the primary tumor needs to be removed to reduce 5 year recurrence from 9% (from
all TXNXM0) to 1%. This line intercepts with a CTC concentration of 9 CTC/L of whole blood and a lesion size of 2.7 mm, and represent the
required sensitivities for radiographic imaging and CTC detection.
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(metastatic). Rate of dissemination can be determined from
the CTC concentration values reported in literature [8-15].
Here we combined literature values with clinical data from
the NCR to obtain estimates for DT, and (metastatic) for
patients. Using this model, we predicted the sensitivity
needed for radiographic imaging and CTC enumeration
for the detection of a primary tumor before DM forma-
tion has occurred.
The major assumptions in the model are:
1) Metastatic efficiency and dissemination rate are
not dependent on doubling time. Considering the
high incidence of recurrence within the first
5 years compared to years 6–15, metastatic
efficiency or dissemination rate are probably
smaller for slower growing tumors. If, for example,
75% of recurrences are found in the first five years
(doubling time < 3 months), 20% of recurrences
in years 5–15 (doubling time 3–9 months), and
5% of recurrences in years 15–25 (doubling time
9–15 months), the metastatic efficiency for 0–3 month
doubling time would be approximately 6-fold higher
than for 3–9 months, and approximately 24-fold
higher than for 9–15 months. A shorter doubling
time reduces the probability of DM; the tumor has a
shorter time to form a metastasis before it is large
enough to be discovered. However, a reduction of
probability of DM by an x-fold shorter doubling time
is negated by a x-fold higher metastatic efficiency. A
6 fold increase in metastatic efficiency and/or
dissemination rate for a fourfold shorter doubling
time would mean that the faster growing tumor has a
higher probability of DM.
2) The rate of dissemination and metastatic efficiency
are independent of cancer type. We need to make
this assumption because 1.) We lack data on CTC
concentrations versus cancer type, and 2.) We lack
data on cancer types for the patients in our data set.
In another study, the five year risk of recurrence for
patients with triple negative breast cancer (11% of
total) was estimated to be 2.6 fold higher than for
patients with other breast cancers (89% of total)
[37]. To assess the impact of a subtype with high
risk of recurrence, we implemented a subgroup of
11% of patients with 2.6 fold higher product of
metastatic efficiency and dissemination rate than the
other 89%, while the average metastatic efficiency
was held constant. The estimated detection limits
did not change due to a higher metastatic efficiency
nor to a higher dissemination rate.
3) The metastatic efficiency does not evolve over time.
While we expect that metastatic efficiency actually
increases over time [16], we lack data describing
such evolution. The high relative probability of
distant metastasis formation just before tumor
discovery implies that the estimated metastatic
efficiency also applies to the period just before
tumor discovery. To obtain a fit between the CTC
data in early stage patients and in metastatic
patients, we applied a single increase in the
dissemination rate of 25-fold, or an increase in the
metastatic efficiency of 10,000-fold. Our rationale
was that the metastatic cell has become efficient at
disseminating and/or metastasizing due to natural
selection by the metastatic cascade and has thus
become genetically more prone to formation of new
metastases [57,58]. We recognize that it is equally
feasible that such evolution occurs more gradually.
4) The transit from primary tumor to metastatic site is
instant. Temporary storage of cells in the bone
marrow, or temporary dormancy at the metastatic
site, would result in a delay in the start of growth,
and thus in an underestimation of the doubling
time. For long delays the recurrence would likely be
pushed outside the 5-year window, and for small
delays the doubling time is marginally affected. For
example, if we assume a typical delay of four
months, the previous doubling time estimate of
1.7 months would become 1.5 months.
5) The probability of DM is defined as the probability
that at least one metastasis was present at the time
of surgery, continues to grow and is discovered once
it has reached a size of 8 mm. Changing the size at
which a tumor is discovered affects the estimated
growth rate. For example, if the typical tumor is
discovered at a size of 15 mm, the estimated
doubling time is 1.5 months instead of 1.7 months.
Data from the NCR was used to determine the prob-
ability for breast cancer DM by T-stage and the time be-
tween surgical intervention and DM. To obtain a patient
group with minimal risk of DM, we included only pa-
tients with complete removal of the tumor after surgical
resection, relatively small tumors (T1,2) and no detect-
able metastasis (NXM0). The NCR recorded data for
DM five years after surgical intervention. From the
time to DM of 32 ± 18 months, we determined a DT of
1.7 ± 0.9 months for DM; threefold faster than the DT
of 5.7 months (range 2.0-11.2) determined from primary
tumor imaging data. A DM with a DT of 5.7 months
would lead to discovery of a DM 9.5 years after initiation
of the DM. Our 5-year (60 month) observation window
is too short to observe tumors with a DT of 5.7 months.
It is likely that our estimate of 1.7 months represents
tumors with aggressive growth rates. Concurrent, the
5-year observation window may select for specific organs,
because aggressive growth rates are more likely in organs
that provide high levels of nutrients and tumor specific
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growth factors. Approximately three quarters of recur-
rences take place in the first five years [59]. With a
15-year observation window we expect to find a doubling
time of 2.7 months. In addition, the literature value for
DT of 5.7 months is determined on primary tumors, while
the model fit DT of 1.7 months is determined on the DM.
The DM may have a different DT than the primary lesion
in the same patient due to natural selection in the meta-
static cascade, differences in the tumor microenvironment
or accumulation of growth enhancing mutations.
From murine studies, we conclude that dissemination
rate is linearly dependent on the diameter of a lesion.
For a diameter of 8 mm (typical T1B) we find a dissem-
ination rate of 280 CTC/h · g tumor (range 90–470) when
we fit the clinical data to our model. This is on the low
end of the range of dissemination rates determined from
the tumor efferent vein in human studies of 90–78,000
CTC/h · g tumor (Additional file 1: Table S3). Dissemin-
ation rates determined in murine models span a very
wide range of 7 orders of magnitude (0.15-8,700,000
CTC/h · g tumor, Additional file 1: Table S2). While this
variation may be caused by differences in the detection
methods used or differences between cell lines, the
variation between murine estimates makes comparison
with our model futile.
Metastatic efficiency in our model is estimated at 1
metastasis per 60 million disseminated tumor cells. This
is substantially less efficient than the murine model me-
dian estimate of 1 metastasis in 14,000 disseminated cells
(range 1 in 170 to 1 in 1 million). The large difference of
metastatic efficiency between murine model and human
model may be attributed to many factors, including use
of cell lines with high metastatic efficiency, the 2,000-
fold difference in size between human and mouse and
the immunodeficiency of most mouse models. A host
specific (immune) response to tumor cells most likely
reduces metastatic efficiency, and may reduce tumor
growth of small lesions. Studies quantifying the impact
of the host response on tumor growth are needed before
inclusion in any model. Murine models suggest that dis-
seminated cells have high survival in circulation and are
efficient at extravasation, Additional file 1: Table S4.
Survival of extravasated cells beyond 2 weeks is estimated
between 4% and 50%, if these tumor cells continue to
survive this would leave a substantial number of dormant
cells scattered throughout the body, up to a million cells
in our model, Additional file 1: Supplemental S4. These
cells may constitute a malignant time-bomb, since dor-
mant cells may be reactivated at a later time [60]. In the
shorter term, metastatic efficiency is limited primarily
by the ability of a disseminated cell to grow in a new site
Table 4.
Based on murine studies in different organs (see
Additional file 1) we expect the model to be applicable
to other cancers. It should be noted that tumors with
high metastatic efficiency, such as melanoma [63] or
non-small cell lung cancer [64] will have substantially
lower numbers of CTC. Similarly, colorectal CTC are
captured in the hepatic microcirculation and are lower
when detected in the peripheral circulation [9,45]. De-
termination of tumor size is more difficult for some
tumor types such as prostate cancer, which will result
in higher error margins in the model parameters.
To determine the probability of metastases in a pa-
tient, three parameters are relevant, the dissemination
rate, the growth rate and the metastatic efficiency. The
dissemination rate can be determined from the CTC con-
centration, the growth rate and metastatic efficiency can
be estimated from the primary tumor or, alternatively,
by genotyping captured CTC. This is supported by the
observation that both CTC concentration and hormone
receptor status from primary tissue information are inde-
pendent prognostic data in multivariate analyses [65,66].
The model can be applied to estimate the probability of
metastases as a function of primary tumor size. Figure 3
illustrates that the model reasonably predicts the prob-
ability of DM for stages T1B to T2. The probability of
DM grows slightly faster in the data than in the model,
which may be caused by a slow increase in dissemination
rate or metastatic efficiency over time. With current im-
aging technology, 94% of detected lesions have a size of
6 mm or more, with a specificity of 40% [67]. From the
data of the NCR, we conclude that current clinical prac-
tice in the Netherlands has similar detection character-
istics, with 95% of the tumors detected when the tumor
is 5 mm or larger, with a median size of 17 mm. The
larger probability of DM for T1A than T1B in the NCR
Table 4 Blood flow to different organ systems [61] and %
of breast cancer patients (N = 432) with distant metastases
in these organs at time of death [62]
Organ Cardiac output (%) Px w/mets (%) % Px w mets/%
cardiac output
Adrenal gl. < 1 9 >9
Pleura < 1 9 >9
Bone 5 12 2.40
Skin 9 7 0.78
Liver 27 a 13 0.48
Brain 13 2 0.15
Lung 100 13 0.13
Kidney 20 2 0.10
Muscle 15 0 0
Other 10 < 3 < 0.3
Included in the table are all organs which receive at least 5% of cardiac
output, or in which metastases were found at autopsy in at least 4% of
patients. Px w mets = patients with metastasis.
a 21% via portal vein, 6% direct.
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data is unexpected and raises the question whether
these small tumors are truly more aggressive, or whether
the difficulty to detect tumors smaller than 5 mm has
caused a sampling bias in the T1A sample.
To implement CTC as a screening tool, the improved
CTC detection will need to have a minimal impact on
the screened patient and to have similar specificity to
radiological imaging. We note that by definition, CTC
enumeration will not detect benign lesions. On the other
hand, CTC detection could have excellent sensitivity and
specificity for malignant lesions if the malignancy of
detected CTC is confirmed with for example whole gen-
ome comparative genome hybridization [68,69].
Conclusions
A model was developed to estimate tumor size and CTC
concentration before distant metastasis occur. To reduce
the overall probability of DM from 9.2% to 1% the tumor
needs to be detected by the time it reaches 2.7 ± 1.6 mm.
Clinical proof of this estimate requires an improvement
in imaging technology that allows routine diagnosis of
tumors smaller than 2.7 mm without a decrease in speci-
ficity of tumor detection. Alternatively, to achieve prob-
ability of DM of 1%, a tumor would need to be detected
when the CTC concentration is 9 ± 6 CTC/L of whole
blood. This requires at least a 15-fold improvement in
the CTC detection limit. Subtypes of breast cancer with
higher growth rate, higher metastatic efficiency, or higher
dissemination rate would affect this estimate, requiring a
smaller lesion, or a lower number of CTC, to be detected
to achieve the overall probability of DM of 1%.
Additional file
Additional file 1: Detection of cancer before metastasis.
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